Covered recipient · General Payments record
AUNG NAING
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$3,375.00
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $3,375.00 | 2 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme LLC | $2,135.00 | 1 |
| Janssen Pharmaceuticals, Inc | $1,240.00 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
AUNG NAING
NPI 1104837590 · CMS profile ID 366226
Allopathic & Osteopathic Physicians / Internal Medicine
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1104837590?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104837590?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). AUNG NAING, NPI 1104837590, CMS profile ID 366226. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104837590?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- AUNG NAING, NPI 1104837590, CMS profile ID 366226, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1104837590?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $3,375.00 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,135.00 | 12/11/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048527513 | CMS |
| Janssen Pharmaceuticals, Inc | $1,240.00 | 03/31/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 987964145 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,918,481.53 | 469 |
| PY2024 | Recipient | $4,531.10 | 4 |
| PY2024 | Principal investigator | $4,445,667.71 | 159 |
| PY2023 | Principal investigator | $4,761,955.67 | 97 |
| PY2022 | Principal investigator | $3,708,621.77 | 334 |
| PY2021 | Principal investigator | $5,802,399.26 | 154 |
| PY2020 | Recipient | $2,459.66 | 4 |
| PY2020 | Principal investigator | $1,927,221.68 | 148 |
| PY2019 | Principal investigator | $5,972,979.75 | 356 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
154 records in PY2021
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $498,432.00 | 12/31/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase II Study for the Evaluation of Efficacy of Pembrolizumab MK-3475 in Patients with Advanced Types of Cancers | No dispute reported | 06/30/2026 | 848758903 |
| Principal investigator 1 | Merck Sharp & Dohme Corporation | $1,007,500.00 | 12/31/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | An Open-label Phase 1b,2a Study of NT-I7 Hyleukin-7 in Combination with Pembrolizumab in Subjects with Relapsed,Refractory Advanced Solid Tumors | No dispute reported | 06/30/2026 | 848767285 |
| Principal investigator 1 | PFIZER INC. | $12,682.29 | 12/23/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832574597 |
| Principal investigator 1 | BioNTech SE | $2,648.60 | 12/22/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT152-01C | No dispute reported | 06/30/2026 | 851137815 |
| Principal investigator 1 | BioNTech SE | $20,039.60 | 12/16/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT152-01C | No dispute reported | 06/30/2026 | 851137735 |
| Principal investigator 1 | EMD Serono, Inc. | $104.80 | 12/16/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842919825 |
| Principal investigator 1 | BioNTech SE | $163,054.46 | 12/09/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT151-01 | No dispute reported | 06/30/2026 | 851137941 |
| Principal investigator 1 | PFIZER INC. | $3,337.17 | 12/08/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832574607 |
| Principal investigator 1 | BioNTech SE | $53,750.00 | 11/24/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT151-01 | No dispute reported | 06/30/2026 | 851137939 |
| Principal investigator 1 | PFIZER INC. | $46,350.71 | 11/24/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832680553 |
| Principal investigator 1 | EMD Serono, Inc. | $51,475.00 | 11/22/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors | No dispute reported | 06/30/2026 | 842914503 |
| Principal investigator 1 | BioNTech SE | $59,834.90 | 11/18/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT152-01C | No dispute reported | 06/30/2026 | 851137603 |
| Principal investigator 1 | Incyte Corporation | $1,862.00 | 11/16/2021 | Non-covered Recipient Entity MD ANDERSON CANCER CENTER | A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831148601 |
| Principal investigator 1 | BioNTech SE | $112,533.93 | 11/10/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT151-01 | No dispute reported | 06/30/2026 | 851137937 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $46,669.25 | 11/09/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | New TED/TCD --- Phase 1 Oncology | No dispute reported | 06/30/2026 | 838651021 |
| Principal investigator 1 | PFIZER INC. | $14,145.36 | 11/05/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832680541 |
| Principal investigator 1 | Incyte Corporation | $1,352.70 | 10/29/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831057047 |
| Principal investigator 1 | Incyte Corporation | $3,316.50 | 10/22/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831057041 |
| Principal investigator 1 | BioNTech SE | $94,492.80 | 10/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT152-01C | No dispute reported | 06/30/2026 | 851137561 |
| Principal investigator 1 | EMD Serono, Inc. | $1,441.60 | 10/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842918317 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 10/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842918551 |
| Principal investigator 1 | PFIZER INC. | $18,694.84 | 10/21/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832680003 |
| Principal investigator 1 | PFIZER INC. | $3,682.85 | 10/08/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832681077 |
| Principal investigator 1 | BioNTech SE | $11,457.38 | 09/23/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT151-01 | No dispute reported | 06/30/2026 | 851137935 |
| Principal investigator 1 | PFIZER INC. | $5,728.79 | 09/22/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832680015 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $149,339.05 | 09/14/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | New TED/TCD --- Phase 1 Oncology | No dispute reported | 06/30/2026 | 838651017 |
| Principal investigator 1 | PFIZER INC. | $859.91 | 09/04/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832681927 |
| Principal investigator 1 | Incyte Corporation | $1,537.20 | 09/03/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831075487 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,911.50 | 08/23/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase IIB TMB High Pan Tumor FA for tTMB | No dispute reported | 06/30/2026 | 819882103 |
| Principal investigator 1 | PFIZER INC. | $3,340.71 | 08/21/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832680831 |
| Principal investigator 1 | BioNTech SE | $30,091.72 | 08/19/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT151-01 | No dispute reported | 06/30/2026 | 851137933 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 08/19/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842910819 |
| Principal investigator 1 | Incyte Corporation | $25.02 | 08/09/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831057011 |
| Principal investigator 1 | Incyte Corporation | $20.26 | 08/09/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831057017 |
| Principal investigator 1 | Incyte Corporation | $116.40 | 08/09/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831057023 |
| Principal investigator 1 | Incyte Corporation | $10,593.90 | 08/06/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831075463 |
| Principal investigator 1 | PFIZER INC. | $8,498.15 | 08/06/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832679759 |
| Principal investigator 1 | BioNTech SE | $15,695.23 | 07/29/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT151-01 | No dispute reported | 06/30/2026 | 851137931 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $286,831.13 | 07/23/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies | No dispute reported | 06/30/2026 | 845834767 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $129.42 | 07/15/2021 | Non-covered Recipient Entity University Of Texas Md Anderson Cancer Center-Investigational Cancer Therapeutics | Phase I IIA FIH CCR8 Mono Combo | No dispute reported | 06/30/2026 | 819904663 |
| Principal investigator 1 | PFIZER INC. | $34,561.98 | 07/09/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832680841 |
| Principal investigator 1 | Deciphera Pharmaceuticals Inc. | $139.00 | 07/07/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A STUDY OF REBASTINIB DCC-2036 IN COMBINATION WITH CARBOPLATIN IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 827891893 |
| Principal investigator 1 | Incyte Corporation | $12,746.70 | 06/30/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831075221 |
| Principal investigator 1 | EMD Serono, Inc. | $23,428.80 | 06/28/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors | No dispute reported | 06/30/2026 | 842897513 |
| Principal investigator 1 | Incyte Corporation | $2,436.07 | 06/28/2021 | Non-covered Recipient Entity MD ANDERSON CANCER CENTER | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831148597 |
| Principal investigator 1 | Incyte Corporation | $264.29 | 06/28/2021 | Non-covered Recipient Entity MD ANDERSON CANCER CENTER | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831148599 |
| Principal investigator 1 | BioNTech SE | $2,619.82 | 06/24/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT151-01 | No dispute reported | 06/30/2026 | 851137929 |
| Principal investigator 1 | PFIZER INC. | $3,682.85 | 06/22/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832680819 |
| Principal investigator 1 | BioNTech SE | $35,827.44 | 06/17/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | BNT151-01 | No dispute reported | 06/30/2026 | 851137927 |
| Principal investigator 1 | EMD Serono, Inc. | $45,537.30 | 06/17/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors | No dispute reported | 06/30/2026 | 842897653 |
| Principal investigator 1 | Incyte Corporation | $1,011.60 | 06/11/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831075197 |
| Principal investigator 1 | Incyte Corporation | $2,089.80 | 06/11/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831075203 |
| Principal investigator 1 | PFIZER INC. | $12,141.86 | 06/05/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832682153 |
| Principal investigator 1 | PFIZER INC. | $2,272.50 | 05/21/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832681915 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 05/20/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842928643 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 05/20/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842928765 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 05/20/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842928839 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 05/20/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842928895 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 05/20/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842928905 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 05/20/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842929029 |
| Principal investigator 1 | Incyte Corporation | $5,904.00 | 05/10/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831075149 |
| Principal investigator 1 | PFIZER INC. | $15,281.13 | 05/07/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832679773 |
| Principal investigator 1 | PFIZER INC. | $22,923.79 | 04/21/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832681941 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $126,597.30 | 04/20/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | New TED/TCD --- Phase 1 Oncology | No dispute reported | 06/30/2026 | 838660865 |
| Principal investigator 1 | Incyte Corporation | $44.75 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056311 |
| Principal investigator 1 | Incyte Corporation | $251.40 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056315 |
| Principal investigator 1 | Incyte Corporation | $43.20 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056321 |
| Principal investigator 1 | Incyte Corporation | $89.50 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056327 |
| Principal investigator 1 | Incyte Corporation | $125.70 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056333 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056339 |
| Principal investigator 1 | Incyte Corporation | $27.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056345 |
| Principal investigator 1 | Incyte Corporation | $71.60 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056351 |
| Principal investigator 1 | Incyte Corporation | $201.12 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056357 |
| Principal investigator 1 | Incyte Corporation | $43.20 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056523 |
| Principal investigator 1 | Incyte Corporation | $43.20 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056527 |
| Principal investigator 1 | Incyte Corporation | $43.20 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056533 |
| Principal investigator 1 | Incyte Corporation | $43.20 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056539 |
| Principal investigator 1 | Incyte Corporation | $27.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056545 |
| Principal investigator 1 | Incyte Corporation | $27.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056551 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056557 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056563 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056569 |
| Principal investigator 1 | Incyte Corporation | $54.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056575 |
| Principal investigator 1 | Incyte Corporation | $27.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056581 |
| Principal investigator 1 | Incyte Corporation | $27.00 | 04/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056587 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $105,478.94 | 04/15/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE IB II OPEN LABEL MULTICENTER STUDY OF MCS110 IN COMBINATION WITH PDR001 IN PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 800618649 |
| Principal investigator 1 | PFIZER INC. | $62,019.65 | 04/09/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832680025 |
| Principal investigator 1 | Incyte Corporation | $107.20 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056363 |
| Principal investigator 1 | Incyte Corporation | $140.64 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056369 |
| Principal investigator 1 | Incyte Corporation | $51.05 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056375 |
| Principal investigator 1 | Incyte Corporation | $194.00 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056381 |
| Principal investigator 1 | Incyte Corporation | $62.55 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056387 |
| Principal investigator 1 | Incyte Corporation | $61.84 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056393 |
| Principal investigator 1 | Incyte Corporation | $107.20 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056593 |
| Principal investigator 1 | Incyte Corporation | $62.55 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056599 |
| Principal investigator 1 | Incyte Corporation | $51.05 | 04/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056605 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 04/06/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842930629 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 04/06/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842930705 |
| Principal investigator 1 | EMD Serono, Inc. | $1,802.00 | 04/06/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. | No dispute reported | 06/30/2026 | 842930711 |
| Principal investigator 1 | Incyte Corporation | $19,489.50 | 03/29/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074523 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,080,000.00 | 03/26/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies | No dispute reported | 06/30/2026 | 845834769 |
| Principal investigator 1 | PFIZER INC. | $2,405.80 | 03/24/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832679783 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $95,032.74 | 03/17/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 800617283 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $277,272.27 | 03/05/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) | No dispute reported | 06/30/2026 | 819882133 |
| Principal investigator 1 | PFIZER INC. | $73,364.57 | 03/05/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY TOLERABILITY PHARMACOKINETIC PHARMACODYNAMIC AND ANTITUMOR ACTIVITY OF PF07209960 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS | No dispute reported | 06/30/2026 | 832681091 |
| Principal investigator 1 | Incyte Corporation | $25.00 | 02/24/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831114731 |
| Principal investigator 1 | Incyte Corporation | $33.00 | 02/24/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831114737 |
| Principal investigator 1 | Incyte Corporation | $33.00 | 02/24/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831114743 |
| Principal investigator 1 | Incyte Corporation | $33.00 | 02/24/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831114749 |
| Principal investigator 1 | Incyte Corporation | $33.00 | 02/24/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831114755 |
| Principal investigator 1 | Incyte Corporation | $33.00 | 02/24/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831114761 |
| Principal investigator 1 | Incyte Corporation | $1,517.40 | 02/09/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831074442 |
| Principal investigator 1 | Incyte Corporation | $64.32 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056129 |
| Principal investigator 1 | Incyte Corporation | $75.06 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056135 |
| Principal investigator 1 | Incyte Corporation | $30.63 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056141 |
| Principal investigator 1 | Incyte Corporation | $91.89 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056147 |
| Principal investigator 1 | Incyte Corporation | $116.40 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056153 |
| Principal investigator 1 | Incyte Corporation | $6.39 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056159 |
| Principal investigator 1 | Incyte Corporation | $2.84 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056165 |
| Principal investigator 1 | Incyte Corporation | $30.92 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056171 |
| Principal investigator 1 | Incyte Corporation | $35.16 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056177 |
| Principal investigator 1 | Incyte Corporation | $12.30 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056183 |
| Principal investigator 1 | Incyte Corporation | $10.20 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056187 |
| Principal investigator 1 | Incyte Corporation | $20.26 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056194 |
| Principal investigator 1 | Incyte Corporation | $1.08 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056201 |
| Principal investigator 1 | Incyte Corporation | $12.24 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056207 |
| Principal investigator 1 | Incyte Corporation | $15.64 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056213 |
| Principal investigator 1 | Incyte Corporation | $65.89 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056219 |
| Principal investigator 1 | Incyte Corporation | $24.08 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056225 |
| Principal investigator 1 | Incyte Corporation | $1.56 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056231 |
| Principal investigator 1 | Incyte Corporation | $2.97 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056237 |
| Principal investigator 1 | Incyte Corporation | $64.32 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056243 |
| Principal investigator 1 | Incyte Corporation | $75.06 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056247 |
| Principal investigator 1 | Incyte Corporation | $6.39 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056255 |
| Principal investigator 1 | Incyte Corporation | $20.26 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056261 |
| Principal investigator 1 | Incyte Corporation | $1.08 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056267 |
| Principal investigator 1 | Incyte Corporation | $12.24 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056273 |
| Principal investigator 1 | Incyte Corporation | $24.08 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056279 |
| Principal investigator 1 | Incyte Corporation | $2.97 | 02/08/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831056286 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $48,531.12 | 01/28/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies or non-Hodgkins Lymphoma | No dispute reported | 06/30/2026 | 845834753 |
| Principal investigator 1 | Incyte Corporation | $3,750.00 | 01/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074395 |
| Principal investigator 1 | Incyte Corporation | $5,625.00 | 01/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074401 |
| Principal investigator 1 | Incyte Corporation | $1,875.00 | 01/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074407 |
| Principal investigator 1 | Incyte Corporation | $25,625.00 | 01/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074413 |
| Principal investigator 1 | Incyte Corporation | $2,500.00 | 01/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074419 |
| Principal investigator 1 | Incyte Corporation | $1,250.00 | 01/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074425 |
| Principal investigator 1 | Incyte Corporation | $31.00 | 01/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074431 |
| Principal investigator 1 | Incyte Corporation | $4,000.00 | 01/21/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1, Open-Label, Multicenter Study of INCB106385 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831074437 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $270,448.94 | 01/20/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE I THROUGH IB AND OR II OPEN LABEL MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF MBG453 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES | No dispute reported | 06/30/2026 | 800618637 |
| Principal investigator 1 | EMD Serono, Inc. | $8,681.40 | 01/19/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase I, First-in-Human, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of M6223 (an Inhibitor of TIGIT) as Single Agent and in Combination with Bintrafusp Alfa (anti-PDL1/ TGF Trap in Participants with Metastatic or Locally Advanced Solid Unresectable Tumors | No dispute reported | 06/30/2026 | 842896663 |
| Principal investigator 1 | Incyte Corporation | $1,371.00 | 01/15/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 831074341 |
| Principal investigator 1 | Incyte Corporation | $166,865.62 | 01/13/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat in Combination With Durvalumab in Subjects With Selected Advanced Solid Tumors | No dispute reported | 06/30/2026 | 831065529 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $58,934.00 | 01/11/2021 | Covered Recipient Teaching Hospital Ut Md Anderson Cancer Center | Phase I II FIH STING Monotherapy Combination in advanced solid tumors | No dispute reported | 06/30/2026 | 819882225 |
| Principal investigator 1 | Eli Lilly and Company | $362,205.57 | 01/04/2021 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A PHASE 1 STUDY OF PEGILODECAKIN (LY3500518) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS | No dispute reported | 06/30/2026 | 819449771 |